| Today’s Big NewsJan 11, 2024 |
|
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now.
|
|
| By Angus Liu Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates, Pfizer’s newly minted chief oncology officer Chris Boshoff, Ph.D., said in an interview. But the company isn’t considering large buyouts at the moment. |
|
|
|
By Max Bayer Takeda cemented itself as a player in the immunology arena when it bought Nimbus' TYK2 inhibitor a year ago, putting it toe-to-toe against Bristol Myers Squibb. Now, the Japanese pharma has detailed just how the drug landed in its pipeline. |
By Conor Hale In a preliminary look at its earnings during the J.P. Morgan Healthcare Conference in San Francisco, the company said it more than doubled its fourth-quarter sales compared to the year prior. |
By Zoey Becker France's Laboratoires Delbert is working with the FDA to bring in its version of Pfizer's Bicillin to the U.S. amid a months-long shortage and a nationwide spike in syphilis cases. |
|
Wednesday, January 24, 2024 | 2pm ET / 11am PT Join industry experts to hear how digital collection of patient-reported outcomes (PROs) can lay the foundation for advancing health equity, which methods can ensure that PROs are relevant for diverse populations, and what challenges and opportunities still lie ahead. Register now.
|
|
By Nick Paul Taylor BioNTech is continuing to add to its sprawling R&D portfolio without denting its cash mountain. Chinese service provider WuXi Biologics is the latest company to feed the biotech’s appetite for assets, accepting a $20 million offer for monoclonal antibodies against two undisclosed targets. |
By Conor Hale CEO Stephen MacMillan took the microphone at the J.P. Morgan Healthcare Conference in San Francisco to describe “the new Hologic” in three words—a medtech company made “bigger, faster and stronger” in the wake of the COVID-19 pandemic. |
By Angus Liu Bluebird bio’s 40% list-price premium for Lyfgenia compared with Vertex and CRISPR Therapeutics’ sickle cell disease drug surprised many industry watchers last month. But bluebird CEO Andrew Obenshain argues the prices for the gene therapy rivals shouldn’t be compared directly. |
By Conor Hale We’ve compiled the biggest medtech news coming out of the 2024 J.P. Morgan Healthcare Conference, from in and around San Francisco and all points beyond. |
By Andrea Park The original FDA nod for Neuralace's Axon Therapy for nerve pain came after a decade of R&D. The road to its next regulatory nod was much shorter. |
By Andrea Park After inking a deal worth up to $75 million to acquire joint pain devicemaker Vyrsa Technologies late last year, Nevro now appears to be trying to lessen the impact of those costs on its bottom line. |
By Kevin Dunleavy With sales declining for aging multiple sclerosis (MS) drug Fampyra, Biogen has exercised an option to return licensing rights to its development and commercialization outside of the United States to Acorda Therapeutics. The move, which becomes effective on January 1 of 2025, ends a 15-year arrangement between the companies. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle.
|
|
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| |
|
